ONCT - Oncternal Therapeutics begins phase 3 study of zilovertamab

• Oncternal Therapeutics ( NASDAQ: ONCT ) said on Tuesday it had begun a Phase 3 global registrational study of zilovertamab (ZILO-301) to treat patients with relapsed/refractory mantle cell lymphoma.
• The Company received its first Institutional Review Board approval for the study and expects to begin patient screening and enrollment.
• "ZILO-301 also represents the first registrational study for a therapeutic targeting the novel ROR1 pathway, which we believe can help address significant unmet needs in multiple hematological malignancies and other solid tumors," the company said.
• ( ONCT ) has rises 2.2% .

For further details see: